Company intelligence / Profile preview

Amazentis

Lausanne, Switzerlandgeneviatechnologies.com ↗

Ownership: Private
Development stage: Commercial

Overview

Amazentis has shown that Mitopure (Urolithin A) supplementation improved muscle strength by 12% after four months in a clinical study. The company's lead product candidate, AMAZ-02, an oral formulation of urolithin A, is currently advancing in two pivotal Phase 2 clinical trials.

Therapeutic areas: OtherRheumatology
Modalities: Nutritional supplementsTherapeutic nutrition
Industry: Biotech

Drug pipeline

1 asset

Urolithin A

Partnerships

Nestlé Health Science

Beyond the preview

Go deeper on Amazentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amazentis.

Explore the full profile